UBS turns cautious on Schott Pharma as glass syringe demand risks mount

UBS downgraded Schott Pharma to neutral from buy and cut its price target to €22.30 from €27, citing risk of weaker glass syringe demand in fiscal 2027–28; shares fell 5% on Monday. UBS lowered 2026–29 EPS forecasts by an average 2.7% and revenue forecasts by 1.2%, with fiscal 2027 EPS of €1.04 versus €1.09 consensus and 2028 EPS of €1.15 versus €1.21. UBS estimates GLP-1 glass syringes account for about 8% of sales and considers Schott less exposed than rivals, while retaining a positive view on injectable GLP-1 and biologics volume growth. Schott’s fiscal 2026 guidance remains 5–6% constant-currency growth and a 27–28% EBITDA margin; the company is expected to provide guidance on Dec. 10.

Analysis

The key risk is not just GLP-1 demand: if capacity released by competitors is redirected into other injectable drugs, utilization and pricing could weaken across glass syringes, broadening the impact beyond the original program exposure. Schott Pharma appears relatively insulated from the specific North American capacity agreements, but that does not protect it from industry-wide supply competition or drug-delivery destocking. Its cartridge mix may soften the shock; it does not eliminate it.

Near term, the Dec. 10 results are the main catalyst: guidance, drug-delivery order trends and any evidence of customer inventory normalization matter more than broker target changes. After a strong share-price run, reduced valuation support leaves less room for execution slippage. Over 6–18 months, sustained injectable and biologics growth could absorb excess capacity, but that thesis requires demand to outrun competitors’ available supply. A guidance cut, weaker drug-delivery sales, or evidence of syringe price/utilization pressure would falsify the relative-resilience case; stable guidance and improving orders would challenge the bearish read.

Contrarian point: extrapolating Stevanato Group’s (STVN) outlook directly to Schott Pharma may overstate Schott’s exposure, but assuming Schott is immune because it reported no impact so far is equally premature. The reported UBS downside/upside cases are wide, so the event risk is meaningful while the near-term signal remains uncertain.

Key Decisions for Investors

• Avoid chasing a fresh short in STVN after its sharp decline; reassess only if subsequent guidance or order data confirms persistent excess capacity rather than a one-off reset.
• For Schott Pharma, wait for Dec. 10 before adding exposure. Track drug-delivery guidance, order trends and commentary on syringe utilization, pricing and customer inventories; a guidance reduction or worsening order commentary would support staying sidelined.
• If holding Schott Pharma, size it as a catalyst-sensitive position rather than a low-risk GLP-1 compounder. The relative-resilience thesis is weakened by evidence that competitors are redirecting spare syringe capacity into non-GLP-1 drugs.
• No high-conviction pair trade yet: a conditional long Schott Pharma versus short STVN is worth revisiting after results only if Schott demonstrates materially better demand resilience and STVN confirms continuing capacity-related pressure.